Is there a minimum patient number, which should be included into the trial?
- Yes, a minimum of 20 patients should be recruited per centre.
How long is the study period?
- Study period is (5-)7 days within a self-selected week until August 30th 2020.
Which patients should be included?
- All patients that match the inclusion/exclusion criteria with planned surgery within study week should be included in the trial (consecutive numbering!). Furthermore, each centre should record how many patients were screened and how many failed/met the different eligibility criteria
What about patients admitted and undergoing surgery during night?
- Patients admitted to the hospital during night and undergoing immediate surgery are not included in the study.
Who is performing the blood test to evaluate cause of anaemia?
- The hospital or any other system that works for you is responsible for performing the blood test.
Who is paying for the anaemia management?
- We do not have any funding to provide compensation. However, hospitals without BUT INTEREST in routine anaemia management should participate in this (5-)7 days prevalence trial because of the following advantages:
- to estimate the number of patients with iron/folate acid/vitamin B12 deficiency and anaemia of chronic kidney disease/inflammation
- to find out which patient group would benefit from treatment and how to set up an anaemia management
- to get a hint about costs
Which patients should be excluded?
- Patients with preoperative autologous blood donation
- Patients with planned revision surgery within the study period
- Patients whose first surgery during hospitalisation was before the start of the study period (the first surgery during hospitalisation must be within the study week)